Physician profile
Roxana Hakimzadeh
NPI 1083605877
$1,487.36
in general payments reported to CMS, 2019-2025
23 companies · $91.57 in 2025
The $91.57 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $33.91 · 2021: $55.24 · 2022: $666 · 2023: $159 · 2024: $245 · 2025: $91.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $178.70 | 2019-2022 | |
| New World Medical,INC. | $177.96 | 2019-2022 | |
| Rxsight INC | $168.87 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $141.82 | 2022-2025 | Tearcare System, Sion Surgical Instrument, Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $129.18 | 2022 | |
| Sun Pharmaceutical Industries INC. | $121.01 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $117.18 | 2024 | |
| Novartis Pharmaceuticals Corporation | $78.91 | 2020-2023 | |
| Abbvie INC. | $57.12 | 2022-2023 | |
| Ocular Therapeutix, INC. | $36.99 | 2024 | Dextenza |
| Glaukos Corporation | $32.34 | 2019 | |
| Horizon Therapeutics Plc | $28.74 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $26.53 | 2023 | Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $25.62 | 2022 | |
| Alcon Vision LLC | $25.07 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $24.30 | 2019 | |
| Amgen INC. | $21.98 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $20.50 | 2021 | |
| Harrow Eye, LLC | $17.40 | 2025 | Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.67 | 2020 | |
| Biotissue Holdings INC. | $14.94 | 2021 | |
| Dompe US, INC. | $13.58 | 2025 | Oxervate |
| Tearlab Corp | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roxana Hakimzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.